R&D Changing Faces: Pharma and biotech, March 2026 A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.
R&D Sponsored A data-driven guide to small molecule drug discovery and dev... A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.
R&D Looking to gene therapy for ocular diseases, with Lance Bald... Lance Baldo, CEO of Beacon Therapeutics, discusses the transformative power of gene therapy to deliver meaningful outcomes for severe ocular diseases.
R&D Redefining drug discovery: Morocco’s biotech strategy for in... Ongoing work in Morocco demonstrates how developing research infrastructure can support innovative approaches grounded in locally generated data.
R&D LSX2026: On a therapeutic vision for ocular disease, with Al... Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases
R&D Human behaviour in cancer screening trials: A variable that ... Behavioural phenomena are particularly consequential in screening and prevention research in oncology.
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
